SITAR 25

Pays: Israël

Langue: anglais

Source: Ministry of Health

Ingrédients actifs:

SITAGLIPTIN AS HYDROCHLORIDE

Disponible depuis:

UNIPHARM TRADING LTD, ISRAEL

Code ATC:

A10BH01

forme pharmaceutique:

FILM COATED TABLETS

Composition:

SITAGLIPTIN AS HYDROCHLORIDE 25 MG

Mode d'administration:

PER OS

Type d'ordonnance:

Required

Fabriqué par:

LABORATORIOS LICONSA S.A., SPAIN

Domaine thérapeutique:

SITAGLIPTIN

indications thérapeutiques:

SITAR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes melitus. Important limitations of use: SITAR should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis as it would not be effective in these settings. SITAR has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using SITAR.

Date de l'autorisation:

2023-05-04

Notice patient

PATIENT PACKAGE INSERT IN ACCORDANCE
WITH THE PHARMACISTS’ REGULATIONS
)PREPARATIONS( – 1986
The medicine is dispensed with a doctor’s
prescription only
Sitar 25
Film-coated tablets
Each film-coated tablet contains:
Sitagliptin )as hydrochloride( 25 mg
Sitar 50
Film-coated tablets
Each film-coated tablet contains:
Sitagliptin )as hydrochloride( 50 mg
Sitar 100
Film-coated tablets
Each film-coated tablet contains:
Sitagliptin )as hydrochloride( 100 mg
For a list of inactive ingredients and allergens in the
preparation, see section 6 “Further information”.
See also section 2.8 “Important information about
some of the ingredients of the medicine”.
Read this leaflet carefully in its entirety before
using the medicine.
• This leaflet contains concise information about the
medicine. If you have further questions, refer to the
doctor or pharmacist.
• This medicine has been prescribed for you. Do
not pass it on to others. It may harm them even if it
seems to you that their medical condition is similar.
• This medicine is not intended for administration to
children and adolescents under 18 years of age.
1.
WHAT IS SITAR INTENDED FOR?
Sitar is indicated as an adjunct to diet and exercise, to
improve glycemic control in adults with type 2 diabetes
mellitus.
Important limitations of use:
Sitar should not be used in patients with type 1
diabetes or for the treatment of diabetic ketoacidosis,
and will not be effective in these situations.
Sitar has not been studied in patients with a history
of pancreatitis. It is unknown whether patients with
a history of pancreatitis are at high risk for the
development of pancreatitis while using Sitar.
Therapeutic group: DPP-4 enzyme inhibitors.
Sitar belongs to a group of medicines called DPP-4
inhibitors )dipeptidyl peptidase-4 inhibitors(, which
are taken orally, and lower blood sugar levels in adult
patients with type 2 diabetes mellitus.
2.
BEFORE USING SITAR
2.1 Do not use Sitar if:
- you are sensitive )allergic( to any of the ingredients
of Sitar )see section 6 �